|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
116.63 USD |
-1.60% | -9.71% | +37.84% | |
April 01, 2025 at 08:18 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Axsome to narrow focus of depression drug trial after limited success in initial run |
08:18am |
RE |
|
Axsome’s depression treatment fails to meet main goal of late-stage study |
07:10am |
RE |
|
Axsome Therapeutics, Inc. Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder with and Without Excessive Daytime Sleepiness |
07:00am |
CI |
|
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating |
Mar. 26 |
MT |
|
Sector Update: Health Care Stocks Steady Premarket Tuesday |
Mar. 25 |
MT |
|
Axsome Therapeutics’ Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint |
Mar. 25 |
MT |
|
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint |
Mar. 25 |
RE |
|
Axsome’s ADHD drug meets main goal in late-stage study |
Mar. 25 |
RE |
|
Axsome Therapeutics’ ADHD drug meets main goal in late-stage study |
Mar. 25 |
RE |
|
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder Achieves Primary Endpoint |
Mar. 25 |
CI |
|
Axsome Therapeutics Resolves Sunosi Patent Case With Hikma |
Mar. 05 |
MT |
|
Axsome Therapeutics Receives FDA Indication in Support of Alzheimer’s Drug Submission |
Mar. 03 |
MT |
|
Axsome Therapeutics, Inc. Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission |
Mar. 03 |
CI |
|
Mizuho Raises Price Target on Axsome Therapeutics to $212 From $195, Maintains Outperform Rating |
Feb. 28 |
MT |
|
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $212 From $195, Maintains Outperform Rating |
Feb. 26 |
MT |
|
Axsome Therapeutics Says Migraine Drug Symbravo Achieves Primary Endpoint in Phase 3 Trial |
Feb. 24 |
MT |
|
Axsome Therapeutics Announces SYMBRAVO® (Meloxicam and Rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inhibitors |
Feb. 24 |
CI |
|
RBC Capital Adjusts Price Target on Axsome Therapeutics to $192 From $143, Keeps Outperform Rating |
Feb. 19 |
MT |
|
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $200 From $176, Maintains Buy Rating |
Feb. 19 |
MT |
|
Truist Securities Raises Price Target on Axsome Therapeutics to $200 From $190, Keeps Buy Rating |
Feb. 18 |
MT |
|
Axsome Therapeutics, Inc., Q4 2024 Earnings Call, Feb 18, 2025 |
Feb. 18 |
|
|
Axsome Therapeutics Q4 Loss Narrows, Revenue Rises |
Feb. 18 |
MT |
|
Earnings Flash (AXSM) Axsome Therapeutics Reports Q4 Revenue $118.8M, vs. FactSet Est of $118.1M |
Feb. 18 |
MT |
|
Earnings Flash (AXSM) Axsome Therapeutics Reports Q4 Loss $-1.54 Per Share, vs. FactSet Est of $-1.32 |
Feb. 18 |
MT |
|
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 18 |
CI |
AXSM: Dynamic Chart
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company’s two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
More about the company
Buy
Last Close Price
116.63USD
Average target price
173.24USD
Spread / Average Target
+48.53%
Consensus
